Bio Preventive Medicine Corp. (BPM) announced that its IVD product, DNlite-DKD uPTM-FetA ELISA kit (aka DNlite-DKD) has received Market Authorization License from Vietnamese Ministry of Health.
Clinically validated DNlite-DKD could relieve global burden of Diabetic Kidney Disease by predicting renal function loss of Diabetic patients. Before Vietnam, it has obtained market authorization from EU, Taiwan, Malaysia, Thailand, Saudi Arabia, United Arab Emirates. With extensively approvals from many countries and regions means that DNlite-DKD has been recognized by international medical and health communities.
According to the International Diabetes Federation (IDF), Vietnam has more than 3.99 million people with diabetes in 2021. The prevalence rate of diabetes is 6.1%, which has doubled in the past ten years. The Vietnamese government has invested as much as 1.67 billion U.S. dollars in diabetes-related medical expenses, highlighting the huge demand for diabetes-related medical services and diagnosis. After DNlite-DKD obtains marketing authorization, BPM will focus on market strategic planning in order to create business growth momentum.